Analytical Biological Services, Inc, a 3 Boomerang Capital (3 Boomerang or 3BC) portfolio company and a leader in biospecimen sourcing, cell culture services and biorepository solutions for the global pharmaceutical and biotechnology industry, has acquired Cureline, Inc. (Cureline), a leading provider of specimen procurement and histology services to the pharmaceutical and life sciences industries. The closing marks the company's first tuck-in acquisition since 3BC's original investment in June 2024.

Founded in 2003 by Olga Potapova, PhD, Cureline has provided many of the world's leading biopharmaceutical companies with mission-critical biospecimens and services for more than 20 years.

Headquartered in South San Francisco, CA, Cureline provides biospecimen procurement and analysis, histology, digital pathology and other research services to the biopharma community from its state-of-the-art facility at the heart of the life sciences community in the Bay Area.

"Cureline has built an exceptional reputation in the biospecimens and research space, and we are excited to welcome their team to ABS. This acquisition meaningfully expands our capacity and expertise while enabling us to remain focused on what matters most for scientific breakthroughs: broader access to biospecimens, flawless execution and outstanding customer experience from initial request to delivery," says Ehab Alramahy, CEO, ABS Bio.

Cureline will strengthen ABS Bio's position as a premier partner in specimen procurement, cell culture and histology. The transaction expands the company's capabilities and scale for pharmaceutical and biotech customers navigating increasingly complex procurement needs and therapeutic programmes.

"Cureline was built on scientific excellence, global collaboration and commitment to partnerships in research and drug discovery. ABS and Cureline are highly complementary in customer focus, regional scope of biospecimen collections and service capabilities. By joining forces, our teams can offer a broader platform supported by a wider biospecimen network, deeper services expertise, and expanded biorepository capabilities," said Olga Potapova, PhD, Founder, Cureline.